Adamalysines as Biomarkers and a Potential Target of Therapy in Colorectal Cancer Patients: Preliminary Results

Table 4

Serum concentrations of ADAM10, ADAM12, ADAM17, and ADAM28 in both groups.

Clinical staging	ADAM10 (ng/ml)			ADAM12 (ng/ml)			ADAM17 (ng/ml)			ADAM28 (ng/ml)
	Min	Max	Mean	Min	Max	Mean	Min	Max	Mean	Min	Max	Mean
CSI	1.7	260.7	140.9	0.6	26.7	5.4	0.65	9.8	2.4	244.8	1226.3	774.8
CSII	9.9	270.7	104.3	0.8	20.7	3.4	0.4	15.5	1.5	21.8	1545.8	835.0
CSIII	20.5	256.3	101.4	1.9	16.4	4.52	0.9	7.6	1.8	17.1	1251.8	619.4
CSIV	79.4	321.8	111.9	2.6	15.8	5.69	0.8	3.8	2.33	479.6	1422.3	1019.7
Control group	0.03	1.14	0.32	0.26	3.81	1.99	0.71	5.25	2.78	1.67	14.36	3.72